2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment

(2017) Robert Dufour et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach

(2017) Nina Scherer et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Can LDL cholesterol be too low? Possible risks of extremely low levels

(2017) A. G. Olsson et al.   JOURNAL OF INTERNAL MEDICINE

USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA

(2017) Shaun G. Goodman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab

(2017) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antidrug Antibodies in Patients Treated with Alirocumab

(2017) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia

(2017) Paolo Rubba et al.   European Journal of Preventive Cardiology

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

(2017) Frederick J Raal et al.   Lancet Diabetes & Endocrinology

Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol

(2017) Robert P. Giugliano et al.   JAMA Cardiology

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia

(2017) Michael J. Koren et al.   JAMA Cardiology

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

(2016) Marc S. Sabatine et al.   AMERICAN HEART JOURNAL

Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial HypercholesterolaemiaHighlights

(2016) Leopoldo Pérez de Isla et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all

(2016) Evan A. Stein   CARDIOVASCULAR DRUGS AND THERAPY

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin TherapyCLINICAL PERSPECTIVE

(2016) Ian Ford et al.   CIRCULATION

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United StatesCLINICAL PERSPECTIVE

(2016) Emil M. deGoma et al.   Circulation-Cardiovascular Genetics

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Determining When to Add Nonstatin Therapy

(2016) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

(2016) Parth Shah et al.   Lipids in Health and Disease

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United StatesCLINICAL PERSPECTIVE

(2016) Emil M. deGoma et al.   Circulation-Cardiovascular Genetics

Cardiac computed tomography imaging in familial hypercholesterolaemia

(2015) Eric J.G. Sijbrands et al.   CURRENT OPINION IN LIPIDOLOGY

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

(2014) Mary A. De Vera et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects

(2014) Catherine Lunven et al.   Cardiovascular Therapeutics

The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups

(2013) Alberico Catapano et al.   Clinical Lipidology

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

(2012) Doralisa Morrone et al.   ATHEROSCLEROSIS

Coronary Computed Tomographic Angiography and Risk of All-Cause Mortality and Nonfatal Myocardial Infarction in Subjects Without Chest Pain Syndrome From the CONFIRM Registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry)

(2012) Iksung Cho et al.   CIRCULATION

Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication

(2012) Marianne Benn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

(2012) Evan A. Stein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry

(2010) Carmen Suárez et al.   VASCULAR MEDICINE

Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

(2009) M. J. Alberts et al.   EUROPEAN HEART JOURNAL

Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease

(2009) Jacob M. van Werkhoven et al.   EUROPEAN HEART JOURNAL

Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors

(2008) R. Alonso et al.   ATHEROSCLEROSIS